Finnish coronavirus vaccine developer Rokote Laboratories Finland secures significant funding
Rokote Laboratories Finland Ltd. has secured total of nine million euros of funding for the development of a coronavirus vaccine to be administered as a nasal spray.
Ferring Ventures SA, Jenny and Antti Wihuri Foundation, and the Finnish Cultural Foundation have made a capital investment of 3.5 million euros in Rokote Laboratories Finland. In addition, Business Finland has granted a 5.5-million-euro loan to the company to support further development and clinical trials of the company’s coronavirus vaccine.
The vaccine is based on gene transfer technology developed by Ylä-Herttuala’s research group, and the technology has already been successfully used in several clinical trials using gene therapy to treat cardiovascular diseases and cancer.